UNITED STATES


SECURITIES AND EXCHANGE COMMISSION


Washington, D.C. 20549


FORM 10-Q/A


(Amendment No. 1)


(Mark One)


x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


For the quarterly period ended March 31, 2013


Or


¬  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


For the transition period from                  to


Commission File Number (001-35348 )


Intermolecular, Inc.


(Exact Name of Registrant as Specified in its Charter)





Delaware20-1616267(State or Other Jurisdiction ofIncorporation or Organization)(I.R.S. EmployerIdentification No.)3011 N. First StreetSan Jose, California95134(Address of Principal Executive Offices)(Zip Code)


(408) 582-5700


(Registrant's Telephone Number, Including Area Code)


N/A


(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)


Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes x  No  ̈


Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes x No o


Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):





Large accelerated fileroAccelerated filerxNon-accelerated filer ̈Smaller reporting companyo(Do not check if a smaller reporting company)





Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes o No x





---




Shares outstanding of the registrant's common stock:


ClassOutstanding as of April 26, 2013Common stock, $0.001 par value44,684,355







































































































































































---










INTERMOLECULAR, INC.


FORM 10-Q/A FOR THE QUARTER ENDED MARCH 31, 2013


TABLE OF CONTENTS


PageExplanatory Note1PART II - OTHER INFORMATIONItem 6.Exhibits2Signatures4



























































---




Explanatory Note


We originally filed our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2013 (the “Original Filing”) with the Securities and Exchange Commission (“SEC”) on May 2, 2013. We are filing this Amendment No. 1 to our Quarterly Report on Form 10-Q (the “Form 10-Q/A” and together with the Original Filing, the “Form 10-Q”) solely to re-file Exhibit 10.20 to the Original Filing (Second Addendum to Collaborative Development Program Agreement, dated March 27, 2013, by and among Toshiba Corporation, SanDisk Corporation and Intermolecular, Inc. (the “Agreement”)) in response to certain comments we received from the SEC in connection with our confidential treatment request that we made for certain portions of the Agreement. As a result of the filing of this Form 10-Q/A, we are also filing as exhibits to this Form 10-Q/A currently-dated certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.


Except for the foregoing, this Form 10-Q/A does not amend the Original Filing in any way and does not modify or update any disclosures contained in the Form 10-Q, which continues to speak as of the original date of the Original Filing (including, but not limited to, any forward-looking statements made in the Original Filing, which have not been revised to reflect events that occurred or facts that became known after the Original Filing, and such forward-looking statements should be read in their historical context). Accordingly, this Form 10-Q/A should be read in conjunction with the Original Filing and our other filings made with the SEC subsequent to the Original Filing.
























































---




PART II - OTHER INFORMATION


ITEM 6.   EXHIBITS


ExhibitIncorporated by ReferenceFiledNumberExhibit DescriptionFormDateNumberHerewith2.1Asset Purchase Agreement by and between Intermolecular, Inc. and Symyx Technologies, Inc. dated as of July 28, 2011 (1)S-1/A9/9/20112.13.1Amended and Restated Certificate of Incorporation of Intermolecular, Inc.10-K3/16/20123.13.2Amended and Restated Bylaws of Intermolecular, Inc.10-K3/16/20123.24.1Specimen Common Stock CertificateS-1/A11/7/20114.14.2Warrant to purchase shares of common stock issued to Timane S.a.r.l. dated June 20, 2008S-17/29/20114.24.3Form of warrant to purchase shares of common stock issued to Toshiba Corporation and SanDisk Corporation dated March 15, 2010S-1/A10/26/20114.34.4Fourth Amended and Restated Investor Rights Agreement dated as of March 4, 2011, by and among Intermolecular, Inc. and certain stockholders named therein, as amended by Amendment No. 1 to Fourth Amended and Restated Investor Rights Agreement dated as of June 14, 2011S-17/29/201110.14.5Secured Promissory Note, issued by the Company to Symyx Technologies, Inc. on November 23, 201110-K3/16/20124.510.20 †Second Addendum to Collaborative Development Program Agreement, dated March 27, 2013, by and among Toshiba Corporation, SanDisk Corporation and Intermolecular, Inc.X10.21 †Tool Purchase and Informatics License Agreement by and between First Solar, Inc. and Intermolecular, Inc., dated February 6, 2013(2)10.22 +Separation Agreement and General Release Agreement, effective March 28, 2013, by and between John R. Behnke and Intermolecular, Inc.(2)10.23 +Employment Agreement dated March 25, 2013 by and between Raj Jammy and Intermolecular, Inc.(2)31.1Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.X31.2Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.X32.1Certification of Chief Executive Officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.(2)32.2Certification of Chief Financial Officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.(2)101.INS*XBRL Instance Document(2)101.SCH*XBRL Taxonomy Extension Schema Document(2)101.CAL*XBRL Taxonomy Extension Calculation Linkbase Document(2)101.DEF*XBRL Taxonomy Extension Definition Linkbase Document(2)101.LAB*XBRL Taxonomy Extension Label Linkbase Document(2)101.PRE*XBRL Taxonomy Extension Presentation Linkbase Document(2)


|    |                                                                                                                                                                                                        
|--- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|(1) | All exhibits, schedules and similar attachments to this exhibit have been omitted. Copies of such exhibits, schedules and similar attachments will be furnished supplementally to the SEC upon request.

|    |                                                                                                                                                               
|--- | --------------------------------------------------------------------------------------------------------------------------------------------------------------
|(2) | Previously filed with the Company's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2013, originally filed with the SEC on May 2, 2013.

†     Certain portions have been omitted pursuant to a confidential treatment request. Omitted information has been filed separately with the SEC.


+     Indicates a management contract or compensatory plan.





---




*     Pursuant to Rule 406T of SEC Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of Section 11 or 12 of the Securities Act of 1933, as amended, and are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under these sections.





SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.





INTERMOLECULAR, INC.(Registrant)Date: September 5, 2013By:/s/ Reed BirnbaumReed BirnbaumInterim Chief Financial Officer